• Clip News: Display Concepts - Clip Distributor Completes a Stunning Exhibition Stand Design  Read More...
  • Clip News: Clip Stand confirmed at Institute of Fundraising November 23rd & 24th, a must for all Charity contacts, come & see us on stand number two!
  • Clip News: Just finalised a stand at World Travel Market for a long standing Clip user!
  • Clip News: The team at Clip are developing,maufacturing and installing a new contemporary brand awareness and hospitality area at its world leading leisure industry clients UK Headquarters
  • Customer comments: Great to hear this from one of our customers "I have not forgotten how useful Clip and your good self were whilst I was at Tensar/Carborundum”.  Our hardworking team did themselves credit...
  • Clip News: Finalised site plans for Shanghai Motor Show, penultimate leg of Saint-Gobains global event programme for 2011, great first year working with this new partner’
  • Clip News: Discussing brief for 12m x 10m stand with Clip in-house design dept for DUK March 2012
  • Clip News: Finalised plans for small stand and external branding at British Free Range Egg Producers Association Conf November 2011
  • Have you seen our online shop for exhibition supplies? View it here...
  • Clip News: Supporting a long standing client again at the Inter Airport Show in Munich by building a 60 square metre stand

Exhibition Stands News

Biogen ''at forefront'' of MS research and development

16 Apr 2009

Pharmaceutical firm Biogen has positioned itself at the forefront of research and development for multiple sclerosis (MS) treatments, it has claimed.

Representatives from the company are set to discuss its work at the 61st annual meeting of the American Academy of Neurology, which takes place between April 25th and May 2nd.

Two of its therapies have been approved for use and additional compounds are currently in development.

Vice-president and chief medical officer Michael Panzara said the company was "redefining success" for MS patients.

"We are even seeing some clinical trial patients who are free from MS disease activity or with physical improvement from what was seen at baseline," he explained.

The company has a compound, known as PEGylated interferon beta-1a, ready to enter Phase III testing with a few months, he added.

Its high titer process for the production of Tysabri (natalizumab) was today (April 16th) approved by the US Food and Drug administration following the December approval of from the European Medicines Agency.
ADNFCR-2086-ID-19125100-ADNFCR